These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 32936233)

  • 21. Validation of the 5-D Itch Scale in Three Ethnic Groups and Exploring Optimal Cutoff Values Using the Itch Numerical Rating Scale.
    Cheung HN; Chan YS; Hsiung NH
    Biomed Res Int; 2021; 2021():7640314. PubMed ID: 34938810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
    Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
    Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
    Stein Gold L; Alonso-Llamazares J; Draelos ZD; Gooderham MJ; Kempers SE; Kircik LH; Lebwohl MG; Papp KA; Pariser DM; Toth DP; Yosipovitch G; Higham RC; Feng A; Berk DR
    Am J Clin Dermatol; 2023 Mar; 24(2):305-313. PubMed ID: 36370336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.
    Eudy-Byrne R; Riggs M; Hawi A; Sciascia T; Rohatagi S
    Br J Clin Pharmacol; 2023 Jul; 89(7):2088-2101. PubMed ID: 36680419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
    Wang Y; Coyne K; Sofen H; Santanello N; Currie B; Zhang Z; Nograles K
    J Dermatolog Treat; 2019 Dec; 30(8):775-783. PubMed ID: 30747550
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
    Silverberg JI; Leshem YA; Calimlim BM; McDonald J; Litcher-Kelly L
    Curr Med Res Opin; 2023 Oct; 39(10):1289-1296. PubMed ID: 37691437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
    von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
    J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
    Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.
    Janmohamed SR; Gwillim EC; Yousaf M; Patel KR; Silverberg JI
    Arch Dermatol Res; 2021 Oct; 313(8):669-677. PubMed ID: 33108524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
    Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
    N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
    Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
    Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
    Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
    Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
    Zirwas MJ; Draelos ZD; DuBois J; Kircik LH; Moore AY; Stein Gold L; Alonso-Llamazares J; Bukhalo M; Bruce S; Eads K; Green LJ; Guenthner ST; Ferris LK; Forman SB; Kempers SE; Lain E; Lynde CW; Pariser DM; Toth DP; Yamauchi PS; Higham RC; Krupa D; Burnett P; Berk DR
    JAMA Dermatol; 2023 Jun; 159(6):613-620. PubMed ID: 37133856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
    Weiner DE; Schaufler T; McCafferty K; Kalantar-Zadeh K; Germain M; Ruessmann D; Morin I; Menzaghi F; Wen W; Ständer S
    Nephrol Dial Transplant; 2024 Jun; 39(7):1125-1137. PubMed ID: 37968132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
    Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
    JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.
    Steinke S; Zeidler C; Riepe C; Bruland P; Soto-Rey I; Storck M; Augustin M; Bobko S; Garcovich S; Legat FJ; Lvov A; Misery L; Osada N; Reich A; Şavk E; Serra-Baldrich E; Streit M; Szepietowski JC; Weger W; Dugas M; Ständer S
    J Am Acad Dermatol; 2018 Sep; 79(3):457-463.e5. PubMed ID: 30119869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus.
    Phan NQ; Blome C; Fritz F; Gerss J; Reich A; Ebata T; Augustin M; Szepietowski JC; Ständer S
    Acta Derm Venereol; 2012 Sep; 92(5):502-7. PubMed ID: 22170091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
    Fang HY; Lian CH
    J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.